CGM Use in Non-insulin Patients With DM2

NCT07128342 | Not Yet Recruiting FDA Device

• 1 other identifier: 1856488
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications, and more recently, as over the counter versions for patients with and or without diabetes who want to better understand how diet and exercise may impact blood sugar levels. However robust evidence supporting that CGM is significantly superior to traditional home fingerstick blood glucose monitoring (FSBGM) in this population is lacking. Thus, Medicare and VHA only authorize use of CGM for patients with diabetes who require daily insulin therapy , unless they meet special criteria such as having hypoglycemia or inability to monitor glucose via traditional FSBGM. Objectives Primary Study Aim: Among veterans with uncontrolled diabetes not requiring insulin therapy who are participating in an intensive multidisciplinary program to improve diabetes control (VDOP), to assess whether use of a CGM compared to use of traditional FSBGM results in greater change in hemoglobin A1c upon VDOP completion and up to 12 months. Secondary study aims: To assess whether use of CGM in this population leads to greater improvement in diet, physical activity, and weight loss upon VDOP completion and up to 12 months. Hypothesis The use of a CGM by Veterans with T2DM who do not use insulin will help them improve their diabetes self - management (diet, physical activity, weight) and glycemic control more so than those using traditional fingerstick glucose monitoring. Methods This will be a prospective "open label" randomized controlled trial where participants will be randomly assigned to CGM (intervention group) or FSBGM (control group) during their participation in VDOP. Relevance to Veterans and VA mission Most Veterans with T2DM do not use insulin. It is important for both, these Veterans and the VA, to learn whether this more costly and somewhat burdensome technology supports improvement in diabetes self-management

Conditions

Diabetes; Type 2 Diabetes (T2DM); Obesity Type 2 Diabetes Mellitus; Non Insulin Dependent Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Glycemic Control

  HbA1c

  12 months

Secondary Outcomes (1)

• Weight loss

  12 months

Study Arms (2)

CGM group

ACTIVE COMPARATOR

This group will receive CGM device for glucose monitoring

Device: CGM Group

FSBG group

ACTIVE COMPARATOR

This group will receive fingerstick device for glucose monitoring

Device: FSBG group

Interventions

CGM Group DEVICE

This group of patients will receive a CGM device to monitor their blood glucoses

CGM group

FSBG group DEVICE

This group of patients will receive a fingerstick blood glucose (FSBG) device for glucose monitoring

FSBG group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Successfully enrolled and ready to begin the VDOP program not on insulin therapy
• Type 2 diabetes by clinical history
• HbA1C between 8.0-12.0% inclusive within 3 months of enrollment
• Assessment by clinician that patient is willing to and able to wear a CGM device
• Stable diabetes medication regimen during the 3 months prior to entry

You may not qualify if:

• Patients already or planned on starting insulin therapy, already on CGM, or those who qualify for CGM under VA policy
• Patients with gestational diabetes or pregnant at time of screening or are planning to become pregnant during the study
• Patients with end stage renal disease (ESRD) on dialysis
• Anticipated acute uses of glucocorticoids (oral, injectable, or IV)
• Acute conditions that impact the HbA1c measurement stability such as GI blood loss, recent (within 3 months of study entry), anticipated red blood cell transfusion or erythropoietin administration
• Known or suspected significant allergy to use the Dexcom sensors
• Planning or currently enrolled on different weight program different from MOVE!
• Participating other clinical trials

Sponsors & Collaborators

• Milwaukee VA Medical Center: lead

MeSH Terms

Conditions

Diabetes Mellitus; Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Central Study Contacts

Carlos E Mendez, MD

CONTACT

414-384-2000; carlos.mendez2@va.gov

Colleen Veenendaal, RN, Research Coordinator

CONTACT

(414) 384-2000; Colleen.Veenendaal@va.gov

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: FED
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Diabetes Program

Study Record Dates

• First Submitted: August 12, 2025
• First Posted: August 18, 2025
• Study Start: November 1, 2025
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): November 1, 2028
• Last Updated: August 18, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share